CYP19A1 and neoplasm: SIRT1-dependent chemotherapy failure is observed in estrogen-dependent breast cancer, in which SIRT1 increases the expression of aromatase; this may contribute to higher intra-tumor levels of estrogen and lower the clinical efficacy of aromatase inhibitors commonly used to treat breast cancer cells MDA-MB231, MCF-7, and T47D [77].